Option chain shows key data for Aptorum Gr's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Aptorum Gr.

Aptorum Gr (NASDAQ:APM) Stock, Option Chain

Aptorum Gr

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADVM

AISP

ANGH

ANVS

AQST

ATER

ATXS

BCAN

BLDE

BNRG

BNTX

CETX

CMAX

DWAC

EGIO

ETAO

HROW

IREN

LFCR

MARA

MNTS

OBLG

OTRK

SEEL

SKIN

SRAD

SWVL

TRUG

TSHA

WORX

WULF

XTLB

Shares of  Lifecore Biomedical, Inc.  (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes.

Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday.

Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

AFRM

AUUD

BTTX

CCTG

FUTU

FWBI

GIII

HEAR

HGAS

HOOD

IMRX

KPLT

MDGL

MOMO

NOVA

PANL

PATH

PERF

PIXY

PRST

PUYI

RAYA

RCMT

RGLS

RMBL

SPRB

SPRO

TCON

UNCY

WIMI

WOOF

Shares of  Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Earnings

Eurozone

Commodities

Global

U.S. stocks traded higher this morning, following the release of PPI data.

Following the market opening Thursday, the Dow traded up 0.11% to 39,084.58 while the NASDAQ rose 0.30% to 16,226.13. The S&amp;P 500 also rose, gaining, 0.14% to 5,172.33.

US Stocks Higher; Producer Prices Rise 0.6% In February

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group Ltd

apM Coin

MORIEN RESOURCES CORP ORD by Morien Resources Corp.

Morien Resources Corp

EAGLE GRAPHITE INC by Eagle Graphite Inc.

APM HUMAN SVCS INTL PTY by APM HUMAN SVCS INTL PTY LTD.

ApartmentLove Inc

ASPERMONT LTD by ASPERMONT LTD.

Amper SA

Aperam SA

Trust for Professional Managers ActivePassive Intermediate Municipal Bond ETF

The Company expects to receive aggregate gross proceeds of US$8.20 million from the Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters an option, exercisable within forty-five (45) days after the closing of the Offering, to purchase up to an additional 307,500 ADSs at the public offering price, less underwriting discounts. The Offering is expected to close on or about November 27, 2024, subject to the satisfaction of customary closing conditions.

IPOs

WYHG

Reported Earlier, Wing Yip Food Prices Its $8.2M Initial Public Offering Of 2.05M American Depositary Shares At $4/ADS

Guidance
In the Group's Annual Report 2023, Cadeler provided guidance for the financial year ending 31 December 2024 indicating that full-year revenue was expected to fall within the range of EUR 225 million to EUR 245 million, while full-year EBITDA was expected to be between EUR 105 million and EUR 125 million. Cadeler has today increased its revenue guidance for the financial year 2024, as it now expects full-year revenue to fall within the range of EUR 243 million to EUR 253 million, principally due to clients calling more options under the Group's existing contracts than was previously assumed, higher vessel utilisation as a result of the Group having secured contracts for the provision of operations and maintenance services between installation projects, and the receipt of termination fees in respect of a vessel reservation agreement. In addition, Cadeler has revised and narrowed its EBITDA guidance within the upper end of the range it has previously communicated, as it now expects full-year EBITDA to range between EUR 115 million and 125 million.

Guidance

CDLR

Cadeler Expects FY24 Revenue Of €243M-€253M (Prior €225M-€245M)

If finalized, the loan would support the construction of Rivian's next facility in Stanton Springs North, near the city of Social Circle, Georgia, substantially expanding the company's domestic production capacity to support demand from the United States and international markets. This loan from DOE would provide significant funding for production of the company's midsize platform, which underpins the R2, a midsize SUV, and the R3/R3X, a midsize crossover. Designed, engineered, and built in America to deliver an incredible combination of capability, function, performance, and pricing, Rivian believes its R2 and R3 vehicle lines will be critical drivers in the company's long-term growth and profitability.

RIVN

Reported Earlier, Rivian Secures Conditional $6.6B DOE Loan Commitment To Expand Electric Vehicle Manufacturing And Development In US

Cadeler Reported Q3 Revenue Of €81M Vs €23M YoY

Financial analyst Jim Cramer&#8216;s recent recommendation to &#8220;own&#8221; Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) stocks has triggered a widespread investor revolt, with social media users loudly proclaiming their intent to do the opposite.
What Happened: CNBC&#8217;s &#8220;Mad Money&#8221; host Cramer&#8217;s Monday statement on X, &#8220;Apple, own it, don&#8217;t trade it!&#8221; quickly became a catalyst for what traders call the &#8216;Inverse Cramer&#8217; phenomenon—a strategy where investors systematically bet against his stock recommendations.
Online commentary ranged from satirical to scathing. One user, Tommy Famous, criticized Cramer as a &#8220;financial QVC&#8221; who has &#8220;led audiences into losses,&#8221; suggesting his recommendations are more entertainment than serious financial advice.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Jim Cramer, you've officially cemented yourself as the ultimate inverse indicator. Every word you utter is like a green light for the opposite trade. ‘Apple, own it, don't trade it'? Nah, that translates to SELL IT IMMEDIATELY and SHORT IT TO THE GROUND. You're not a market…
&mdash; Tommy Famous (@TommyBeFamous) <a href="https://twitter.com/TommyBeFamous/status/1861055066964123941?ref_src=twsrc%5Etfw">November 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/global/24/11/42179729/as-nvidia-maintains-chip-supremacy-jim-cramer-says-the-so-called-enemies-of-semiconductor-giant-arent-really-enemies">As Nvidia Maintains Chip Supremacy, Jim Cramer Says Foes Of Semiconductor Giant &#8216;Aren&#8217;t Really Enemies&#8217;</a>
Notable social media reactions included Thomas Peters <a href="https://x.com/thomasopeters/status/1861106660028358992">describing</a> it as &#8220;a great run&#8221; but ultimately follows the Inverse Cramer strategy. Another user <a href="https://x.com/Kyl0Z3n/status/1861062070470332662">humorously</a> suggested it&#8217;s time to sell Apple shares. Some users even pledged to <a href="https://x.com/thecryptomars/status/1861055235235422225">switch</a> technology brands in response. 
The phenomenon isn&#8217;t new. In October 2022, Tuttle Capital launched ETFs specifically designed to track and potentially profit from Cramer&#8217;s stock picks—including an &#8220;Inverse Cramer&#8221; fund that recently announced its shutdown.
Matthew Tuttle, CEO of Tuttle Capital, stated the ETF&#8217;s original mission was to &#8220;point out the danger of following TV stock pickers&#8221; and demonstrate the <a href="https://www.benzinga.com/etfs/specialty-etfs/24/01/36793492/exclusive-inverse-cramer-etf-shuts-down-how-the-magnificent-7-stocks-factor-in-and-a-broken-c">lack of consistent accountability</a> in financial media recommendations.
It is interesting to note that Cramer also predicted Vice President Kamala Harris's victory over now President-elect Donald Trump in the 2024 election on Nov. 4, <a href="https://www.cnbc.com/2024/11/04/cramer-says-mondays-action-suggests-some-anticipate-a-harris-win.html">according</a> to CNBC. "I'm not sure the market's right about what a Harris presidency would mean for business, but at least now we have a blueprint for what Wall Street thinks it'll mean," he said.
Price Action: Apple&#8217;s stock closed Monday at $232.87, up 1.31% for the day, with a year-to-date gain of 25.44%, according to <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42180029/ark-invest-shakes-up-portfolio-with-big-tesla-and-amazon-trades">Cathie Wood-Led Ark Invest&#8217;s Latest Portfolio Maneuver: Dumps Tesla And Palantir Shares, Buys Amazon And AMD Stock</a></li>
</ul>
Image via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

Equities

Tech

AAPL

Jim Cramer's Apple Endorsement Sparks 'Inverse Cramer' Backlash As Social Media Users Mock His 'Own It' Advice

Reported Earlier, Replimune Prices $140M Upsized Public Offering Of&nbsp;6,923,000 Common Shares At $13/Share

REPL

Reported Earlier, Replimune Prices $140M Upsized Public Offering Of 6,923,000 Common Shares At $13/Share

SKYSCRAPER-01 is a global Phase III, randomized, double-blinded study evaluating tiragolumab plus Tecentriq compared to Tecentriq alone in 534 patients with PD-L1-high previously untreated, locally advanced unresectable or metastatic NSCLC. Patients were randomized 1:1 to receive either tiragolumab plus Tecentriq or placebo plus Tecentriq, until disease progression, loss of clinical benefit, or unacceptable toxicity. The study did not reach the primary endpoint of overall survival at the final analysis. The overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified. The detailed data will be presented at a medical meeting in 2025.

RHHBF

RHHBY

RHHVF

Roche's Genentech Provides Update On SKYSCRAPER-01 Phase III Study In PD-L1-High NSCLC Patients

Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion
Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and genetic medicines as part of Roche's Pharmaceuticals

PSTX

Poseida Therapeutics To Be Acquired bB Roche In $1.5B Deal, Stockholders To Receive Up To $13/ Share In Cash

NASA has selected Elon Musk&#8216;s SpaceX to provide launch services for a rotorcraft lander mission aimed at exploring the largest moon of the planet Saturn in July 2028
What Happened: The deal is priced at about $256.6 million, including launch services and other related costs. 
The mission is expected to fly in the period from July 5 to July 25, 2028, on a SpaceX Falcon Heavy rocket from Florida to explore the moon called Titan. 
&#8220;Dragonfly centers on novel approach to planetary exploration, employing a rotorcraft-lander to travel between and sample diverse sites on Saturn's largest moon,&#8221; NASA said in a statement.
The mission is aimed at identifying the habitability of Titan's environment and searching for chemical indications of whether water-based or hydrocarbon-based life once existed on Saturn's moon, among other goals.
Why It Matters: SpaceX has multiple contracts with NASA to fly astronauts and cargo to the International Space Station (ISS) and also to <a href="https://www.benzinga.com/news/24/07/39870115/spacex-ceo-elon-musk-says-safe-destruction-of-international-space-station-will-be-a-very-dramatic-ev">bring down the space station</a> upon its retirement around 2030. 
NASA is also relying on a particular version of SpaceX&#8217;s Starship launch vehicle called the <a href="https://www.benzinga.com/24/11/42108681/spacex-shows-off-conceptual-version-of-starship-which-will-help-humans-land-back-on-moon-in-over-50-yrs">Human Landing System or HLS</a> to enable astronauts to land back on the surface of the Moon for the first time since 1972.
During the Artemis 3 mission, slated for no earlier than September 2026, the Starship HLS will be launched first and it will wait for NASA's Orion spacecraft in lunar orbit after filling its tanks in space. Once the Orion spacecraft arrives, the HLS will dock with it. Two of the four crew members on the mission will transfer from Orion to Starship and descend to the surface of the moon.
The last time humans set foot on the Moon was in 1972 <a href="https://www.benzinga.com/news/24/01/36692749/just-a-worse-version-of-apollo-elon-musk-baffled-by-nasa-veterans-push-to-ditch-spacex-blue-origin-a" target="_blank" rel="noreferrer noopener">with Apollo 17</a>. Since then, no crew has traveled beyond low-Earth orbit.
While SpaceX is not yet listed on the exchanges, investors can leverage Destiny Tech100 Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NYSE">DXYZ</a>) and Cathie Wood&#8216;s Ark Venture Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARKVX#NASDAQ">ARKVX</a>) to participate in the Musk-led space company's growth.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42058338/byd-makes-a-million-nevs-in-less-than-2-months" target="_blank" rel="noreferrer noopener">BYD Makes A Million NEVs In Less Than 2 Months After Beating Tesla For The First Time Since 2022 In Quarterly Revenue</a></li>
</ul>
Photo courtesy: NASA

SPACE

ARKVX

DXYZ

SpaceX Falcon Heavy To Launch NASA's Dragonfly Mission To Saturn's Largest Moon In 2028

The Company intends to use the net proceeds of this offering, together with cash on hand, including from recent sales under the Company's "at the market" offering program, to repay the $478.0 million mortgage loan with a fixed effective interest rate of approximately 9.0% and which is secured by its Washington Square property. Pending such use, the Compa

Macerich Prices Upsized $395M Public Offering Of 20M Common Shares At $19.75/Share

Nokia and du conclude successful transport network slicing trial in UAE
<ul>
<li>Nokia network slicing technology will help du tailor segments customized to user needs.</li>
<li>The first of its kind in the region, the live transport network slicing deployment will cater to specific requirements for bandwidth, latency, and reliability.</li>
</ul>

Nokia And du Complete Successful Trial Of Transport Network Slicing In The UAE

Telegram has reported significant financial growth in the first half of 2024, with revenue reaching $525 million, driven by strong performance in cryptocurrency holdings. This is despite ongoing legal challenges facing its CEO, Pavel Durov.
What Happened: Telegram&#8217;s financial disclosures indicate that the company has benefited from the rising value of its cryptocurrency holdings, which have grown to $1.3 billion, <a href="https://www.ft.com/content/a48acdae-6a6c-4073-894f-89ef5cf8b185">reported</a> Financial Times, citing the company's unaudited financial statements.
This increase, along with proceeds from selling Toncoins, has provided a financial cushion for the Dubai-based firm amid Durov&#8217;s legal troubles.
In August, Durov was detained by <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40558693/telegram-ceo-pavel-durov-faces-12-serious-charges-french-prosecutor-reveals">French authorities in Paris</a>, facing preliminary charges related to alleged criminal activities on the platform.&nbsp;
See Also: <a href="https://www.benzinga.com/24/11/42154224/weekend-round-up-ai-dominates-headlines-with-nvidia-elon-musk-and-hollywoods-big-names?itm_source=parsely-api">Weekend Round-Up: AI Dominates Headlines With Nvidia, Elon Musk, And Hollywood&#8217;s Big Names</a>
Despite these challenges, Telegram informed investors that the situation has not materially impacted its operations.
The company generated $225 million from a one-time deal involving Toncoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TON</a>), initially developed by Telegram but now managed by an open-source community. 
Telegram&#8217;s financial statements also show a post-tax profit of $335 million for the first half of the year.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: Telegram&#8217;s financial health has been under scrutiny, especially with reports suggesting a <a href="https://www.benzinga.com/news/24/09/40669018/telegrams-financial-health-in-question-a-roadblock-to-30b-ipo">loss of $108 million on revenue</a> of $342 million in the previous year.
Despite these challenges, the company has been eyeing a $30 billion IPO in 2026. It remains focused on monetization through ads and premium subscriptions.
A significant portion of Telegram&#8217;s revenue, over 40%, is derived from <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40659490/telegram-derives-40-of-its-revenue-from-crypto-related-operations">crypto-related operations</a>, including its integrated wallet and sale of collectibles.
This reliance on cryptocurrency has provided a financial buffer amid legal challenges.
Additionally, <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41437710/v3v-ventures-invests-5-million-in-premium-telegram-usernames-seizing-unique-advantages-to-">investments like the $5 million</a> by V3V Ventures in premium Telegram usernames highlight the platform&#8217;s potential in the crypto space, as these usernames are seen as valuable assets for building crypto channels.
Price Action: Toncoin is priced at $6.26, reflecting a 2.16% rise over the past 24 hours. However, its trading volume has declined by 15.18%, amounting to $626.53 million at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Check out more of Benzinga's Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42155932/apple-black-friday-2024-get-up-to-200-in-gift-cards-on-iphones-macs-airpods-and-more-heres-everything-you-need-to-know?itm_source=parsely-api">Apple&#8217;s 2024 Black Friday Deals: Gift Cards Over Discounts — Here&#8217;s What You&#8217;ll Get</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.

Social Media

Media

$TON

Telegram's $1.3B Crypto Windfall Shields Business Amid Pavel Durov's Legal Troubles, Toncoin Emerges As The Golden Goose

Former Treasury Secretary Larry Summers predicts potentially significant economic disruption under a potential President-elect Donald Trump&#8216;s administration, cautioning that proposed economic policies could trigger an inflation shock more substantial than recent experiences.
What Happened: In a recent interview, Summers highlighted two primary concerns about the proposed economic agenda: massive demand-side stimulus and substantial supply-side disruptions. The critical components include widespread tax cuts, potential budget deficit expansion, and comprehensive tariff implementations.
&#8220;If they were literally implemented, I have little doubt the Trump program is a far larger stimulus to inflation than anything President [Joe] Biden enacted,&#8221; Summers told CNN.
&#8220;Markets go up, markets go down. Their record in predicting inflation isn&#8217;t very good,&#8221; Summers said. 
Key inflationary risks include:
<ol>
<li>Widespread Tax Cuts: Potentially bloating the federal budget deficit</li>
<li>Across-Board Tariffs: Substantial increases on Chinese goods and imports</li>
<li>Labor Market Disruptions: Potential massive worker deportations creating labor shortages</li>
</ol>
See Also: <a href="https://www.benzinga.com/24/11/42180029/ark-invest-shakes-up-portfolio-with-big-tesla-and-amazon-trades">Want To Invest In Elon Musk&#8217;s Private Companies Like SpaceX And xAI? Here&#8217;s How You Can Do It Via This Cathie-Wood ETF</a>
Why It Matters: Supporting economic analysis from Goldman Sachs reinforces Summers&#8217; concerns. The investment bank estimates a universal 10% tariff could push inflation back to 3%, raising core personal consumption <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42042411/inflation-could-surge-to-3-if-trump-applies-universal-tariffs-goldman-sachs">expenditures inflation by 0.9-1.2 percentage points</a>.
Market indicators currently show resilience. S&amp;P 500 tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) has gained 3.61%, trading at $597.53, while Nasdaq-100 Index tracked by Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) increased 2.92% to $506.59, according to <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Summers emphasized the potential systemic risks, warning that special economic deals could undermine the rule-based market economy that has historically supported robust U.S. market valuations.
The potential economic shifts come amid a complex fiscal landscape, with the U.S. federal budget deficit projected to reach $1.7 trillion in 2024 and the <a href="https://www.benzinga.com/government/24/10/41461338/imf-upwardly-revises-us-economic-growth-but-warns-under-current-policies-the-us-public-debt-is-not-s">debt-to-GDP ratio approaching 120%</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42180029/ark-invest-shakes-up-portfolio-with-big-tesla-and-amazon-trades">Cathie Wood-Led Ark Invest&#8217;s Latest Portfolio Maneuver: Dumps Tesla And Palantir Shares, Buys Amazon And AMD Stock</a></li>
</ul>
Image Via Flickr
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

Economics

ETFs

Larry Summers Warns Trump Policies Could Push Prices Higher Than Biden's Actions: Markets Not A Good Predictor Of Inflation

Macro Economic Events

Econ #s

BBJP

WisdomTree Trust Japan Total Dividend Fund

Bank of Japan Core Consumer Price Index (YoY) 1.5% Vs. 1.8% Est.; 1.7% Prior

Asset management firm VanEck&nbsp;expressed optimism at El Salvador&#8217;s bold Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) bet, terming it as a model of innovation for the emerging world.
What Happened: A report penned by Matthew Sigel, VanEck&#8217;s Head of Digital Assets Research, took stock of the Central American nation&#8217;s experience with Bitcoin and its positive impact.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">How El Salvador Became Latin America&#39;s Comeback Story: New VanEck Research <a href="https://t.co/mygU0TbTJs">https://t.co/mygU0TbTJs</a>
&mdash; Nayib Bukele (@nayibbukele) <a href="https://twitter.com/nayibbukele/status/1861123139788255290?ref_src=twsrc%5Etfw">November 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The report highlighted that nearly 8% of Salvadorans have&nbsp;used Bitcoin for transactions by 2024, terming it a &#8220;meaningful step&#8221; forward for a country with traditionally low electronic payment adoption rates.
Sigel touched down on the country&#8217;s soaring Bitcoin reserves, which represented 1.6% of the country&#8217;s GDP. 
The idea of a &#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/23/12/36192059/el-salvadors-volcanic-bitcoin-bond-approval-sets-stage-to-build-a-crypto-city">Volcano Bond</a>,&#8221; the proceeds of which are aimed to fund the development of Bitcoin City, an economic zone powered by geothermal energy, was also lauded. 
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42155055/crypto-analyst-bitcoin-poised-to-skyrocket-to-180k-and-eventually-top-1m">Crypto Analyst: Bitcoin Poised To Skyrocket To $180K and &#8216;Eventually&#8217; Top $1M</a>
Furthermore, VanEck bet on the country&#8217;s potential as a clean energy-powered Bitcoin mining hub. Interestingly, President Nayib Bukele <a href="https://www.benzinga.com/24/11/42157461/el-salvadors-nayib-bukele-fancies-the-idea-of-renting-volcanoes-to-mine-bitcoin">floated</a> the "rent your volcano to mine&nbsp;Bitcoin&#8221; idea just a day before.
The report also foresaw strong collaboration between the incoming Donald Trump <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42122348/trumps-planned-crypto-council-may-oversee-bitcoin-reserve-report">administration</a> and El Salvador.
&#8220;With Trump's well-documented support for Bitcoin and focus on reshoring and "friend-shoring" supply chains, El Salvador could emerge as a strategic partner in U.S. efforts to build regional alliances.&#8221;
Why It Matters: El Salvador has doubled down on Bitcoin ever since adopting the world&#8217;s largest digital currency as a legal tender in 2021. The country has adopted a plan&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37763988/pro-bitcoin-president-nayib-bukele-says-el-salvador-will-purchase-btc-daily-until-king-cry" target="_blank" rel="noreferrer noopener">to buy one Bitcoin every day</a>, until it becomes unaffordable with fiat currencies.
As of this writing, El Salvador&nbsp;<a href="https://bitcoin.gob.sv/" target="_blank" rel="noreferrer noopener">holds&nbsp;</a>5,945.77 Bitcoins in its treasury, worth nearly $561 million at current market prices.
But despite the promising figures, the Bitcoin adoption in El Salvador <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40644084/el-salvador-president-nayib-bukele-says-bitcoin-uptake-hasnt-been-a-resounding-success-we-">has not been a resounding success</a>. 
Earlier in August, President Bukele admitted that the uptake of Bitcoin in the country hasn&#8217;t been as widespread as anticipated. However, he emphasized that the government never forced anyone to adopt it, offering it as an option instead.
Price Action: As of this writing, Bitcoin was exchanging hands at $94,259.83, down 3.74% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Photo Courtesy: Shutterstock.com
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42154900/crypto-expert-who-called-2022-market-crash-warns-about-bitcoin">Crypto Expert Who Called 2022 Market Crash Warns About Bitcoin</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Pro-Bitcoin Trump Administration Could See El Salvador Emerging As US 'Strategic Partner,' Says VanEck

Shares of Brightcove Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOV#NASDAQ">BCOV</a>) soared 35.42% on Monday to close at $4.32 following news of Halper Sadeh LLC's investigation into the fairness of the company's proposed sale to Bending Spoons for $4.45 per share in cash. 
What Happened: The stock remains volatile, slightly dipping 0.23% in after-hours trading. Year-to-date, BCOV has gained 73.49%, though it is down nearly 70% from its 2021 high of $24.43, according to <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
The legal firm is probing whether Brightcove's board secured optimal value for shareholders, citing concerns that the deal may undervalue the company. Halper Sadeh may seek higher compensation or additional disclosures.
This development comes amid a long-term decline in BCOV's valuation, with the stock trading significantly below its all-time high of $24.80 reached in 2012. 
The investigation underscores shareholder apprehension over whether the board has upheld its fiduciary duties in the merger process.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42179823/opi-shares-surge-over-44-as-debt-refinancing-plan-offers-340m-solution-for-2025-notes">OPI Shares Surge Over 44% As Debt Refinancing Plan Offers $340M Solution For 2025 Notes</a></li>
</ul>
Image via Pexels
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

BCOV

Brightcove Stock Jumps 35% Amid Legal Probe Into $4.45 Per Share Acquisition Deal

Cathie Wood's ARK Venture Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARKVX#NASDAQ">ARKVX</a>) now offers investors a way to access private companies led by Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk, including SpaceX, X, formerly Twitter, and xAI.
What Happened: On Monday, Wood took to X, and shared that the ARK Venture Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARKVX#NASDAQ">ARKVX</a>), managed by ARK Invest, has opened up an investment opportunity in Musk&#8217;s private ventures.
This includes SpaceX, the aerospace manufacturer and space transportation company; X, the rebranded social media platform previously known as Twitter; and xAI, Musk's artificial intelligence company.&nbsp;
By investing in this fund, individuals can gain indirect exposure to these high-profile companies that are not publicly traded.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42122886/cathie-woods-3-8-million-bitcoin-vision-met-with-doubt-83-say-not-by-2030">Cathie Wood&#8217;s $3.8 Million Bitcoin Vision Met With Doubt: 83% Say Not By 2030</a>
In the ARK Venture Fund's portfolio, SpaceX is the most significant holding, accounting for 12.7% of the fund's total weight.
X Corp. holds a smaller share at 0.65%, while xAI represents 1.5% of the portfolio. Musk's EV company Tesla remains part of the fund with a 0.5% weight.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We are known for our early investment in <a href="https://twitter.com/Tesla?ref_src=twsrc%5Etfw">@Tesla</a>. Now, investors can access <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a>&#39;s private companies like <a href="https://twitter.com/SpaceX?ref_src=twsrc%5Etfw">@SpaceX</a>, <a href="https://twitter.com/X?ref_src=twsrc%5Etfw">@X</a>, and <a href="https://twitter.com/xai?ref_src=twsrc%5Etfw">@XAI</a> in the ARK Venture Fund. To learn about the Fund and view current holdings, click here: <a href="https://t.co/sKsHEfyphp">https://t.co/sKsHEfyphp</a>. Holdings are subject to change. <a href="https://t.co/dPrsueLw92">pic.twitter.com/dPrsueLw92</a>
&mdash; Cathie Wood (@CathieDWood) <a href="https://twitter.com/CathieDWood/status/1861073282348241040?ref_src=twsrc%5Etfw">November 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Previously, it was reported that SpaceX was planning to launch a tender offer next month, allowing the sale of shares at $135 each, which would value the <a href="https://www.benzinga.com/24/11/42022150/spacex-to-launch-tender-offer-valuing-company-at-over-250-billion-report">company at over $250 billion</a>.
On the other hand, Fidelity&#8217;s latest valuation <a href="https://www.benzinga.com/top-stories/24/10/41603930/trump-vs-musk-djt-stock-worth-more-than-latest-x-valuation-thanks-to-2024-election-run-up">estimates X at $9.4 billion</a>, a sharp drop from its $44 billion valuation in 2022 when Musk acquired the company.
However, following major advertisers exodus, things appear to be getting better for Musk's social media platform.
Earlier this month, Musk thanked major brands such as IBM, Walt Disney Co., Comcast, and Warner Bros. Discovery for returning to advertise on X.
After the U.S. 2024 Presidential election, reports indicated that some advertisers are considering returning to X to align with both Musk and President-Elect Donald Trump.
Meanwhile, Musk&#8217;s AI startup, xAI, is reportedly seeking to raise as much as $6 billion to acquire 100,000 Nvidia Corporation chips. This new funding round would <a href="https://www.benzinga.com/24/11/42022077/elon-musks-xai-seeks-6b-at-50b-valuation-to-acquire-100k-nvidia-chips-for-memphis-data-center">value xAI at $50 billion</a>, more than twice its previous valuation of $24 billion.
Price Action: ARK Venture Fund ended Monday&#8217;s regular session up 0.43%, reaching $28.22, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Image via Flickr
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42180029/ark-invest-shakes-up-portfolio-with-big-tesla-and-amazon-trades">Cathie Wood-Led Ark Invest&#8217;s Latest Portfolio Maneuver: Dumps Tesla And Palantir Shares, Buys Amazon And AMD Stock</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

TSLA

Want To Invest In Elon Musk's Private Companies Like SpaceX And xAI? Here's How You Can Do It Via This Cathie-Wood ETF

Renowned economist&nbsp;Peter Schiff&nbsp;came hard at the U.S. government&#8217;s endorsement of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), predicting potential economic consequences.
What Happened: On Monday, Schiff took to X to express his concerns over the incoming Donald Trump administration&#8217;s bet on the world&#8217;s leading cryptocurrency.
&#8220;Thanks to the Trump administration&#8217;s&nbsp;picking Bitcoin, Wall Street is&nbsp;winning bigly misallocating capital to&nbsp;Bitcoin and related value-destroying businesses,&#8221; Schiff stated.
Schiff&#8217;s remarks appeared to be directed at MicroStrategy Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) aggressive Bitcoin buying strategy, now being emulated by other Wall Street <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42179537/rumble-bets-on-bitcoin-with-new-treasury-strategy-ceo-calls-it-an-excellent-addition">companies </a>like Rumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>). 
In what appeared to be a dig at Trump&#8217;s popular &#8216;Make America Great Again&#8217; slogan, Schiff said that becoming a Bitcoin superpower would make &#8220;America weaker.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">When government picks winners and losers, it usually picks losers. Thanks to the <a href="https://twitter.com/hashtag/Trump?src=hash&amp;ref_src=twsrc%5Etfw">#Trump</a> administration&#39;s picking <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a>, Wall Street is winning bigly misallocating capital to Bitcoin and related value-destroying businesses. Becoming the Bitcoin superpower makes America weaker.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1861034748522414500?ref_src=twsrc%5Etfw">November 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42176684/exclusive-tim-draper-predicts-bitcoin-to-reach-120k-by-end-of-2024-250k-in-2025">EXCLUSIVE: Tim Draper Predicts Bitcoin To Reach $120K By End Of 2024, $250K In 2025</a>
Why It Matters: Schiff&#8217;s comments come in the wake of his previous warnings about the potential economic catastrophe that could result from the U.S. government establishing a strategic Bitcoin reserve. 
He warned that the government would have to print more dollars to buy additional Bitcoin, which could <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41886523/peter-schiff-us-bitcoin-reserve-could-destroy-dollar-predicts-its-highly-unlikely-to-happen">spiral into hyperinflation and severely devalue the dollar</a>.
The staunch Bitcoin critic has also been unsparing in his attack on Michael Saylor&#8217;s MicroStrategy, the firm currently hogging all the limelight because of its <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42159139/microstrategy-shares-rise-in-monday-pre-market-as-michael-saylor-reveals-mstr-generating-500m-daily-amid-bitcoins-surge">aggressive BTC purchases.</a> He&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41478505/peter-schiff-predicts-a-bloodbath-for-microstrategy-stock-calls-it-the-most-overvalued-on-" target="_blank" rel="noreferrer noopener">predicted a ‘bloodbath'</a>&nbsp;for MicroStrategy's stock, terming it the most overvalued on the MSCI World Index.
Despite Schiff&#8217;s criticism, analysts&nbsp;argue&nbsp;that establishing a Bitcoin reserve would lend <a href="https://blog.coinshares.com/how-trumps-victory-could-boost-bitcoin-s-prospects-c5bb8d3c5bc8">Bitcoin historic legitimacy</a> and drive institutional interest, potentially accelerating its growth and pushing its value to unprecedented levels.
Price Action: At the time of writing, Bitcoin was trading at $94,547.92, sliding 3.16% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. 
Image via Wikimedia Commons
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42163156/why-bitcoins-rally-is-stalling-below-100000">Why Bitcoin&#8217;s Rally Is Stalling Below $100,000</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

MSTR

Peter Schiff Warns Trump's Bitcoin Support Could Lead To Economic Chaos, Make America 'Weaker' As Wall Street Misallocates 'Bigly'

On Monday, Cathie Wood&#8217;s Ark Invest made significant trades involving Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) and Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>). These trades were part of a series of strategic moves made by the investment firm.
The Tesla Trade
Ark Invest sold 20,552 Tesla shares across two of its ETFs. The ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) fund sold 13,136 shares, while the ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) fund sold 7,416 shares. The total value of the sold shares, based on the closing price of $338.59, amounts to approximately $7 million. This move comes amidst news that Tesla vehicles <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42175967/whats-going-on-with-tesla-stock-today-3">may not be eligible</a> for rebates under a new California consumer rebates proposal, causing Tesla shares to close lower on Monday.
The Amazon Trade
Ark Invest&#8217;s ARKQ fund bought 19,747 shares of Amazon. The value of this trade, calculated from the closing price of $201.45, is approximately $4 million. This purchase follows <a href="https://www.benzinga.com/24/11/42176396/amazon-anthropic">Amazon&#8217;s recent investment</a> of $8 billion in artificial intelligence research and development company, Anthropic. Amazon&#8217;s partnership with Anthropic is expected to be mutually beneficial, with Anthropic naming Amazon Web Services as its primary training partner and cloud provider. The Palantir Trade
On Monday, Ark sold 26,047 shares of Palantir worth $1.7 million through its ARKK ETF.
Ark Invest&#8217;s move to trade in PLTR follows a significant endorsement of the artificial intelligence software sector by Wedbush Securities. The firm&#8217;s Managing Director, Dan Ives, has predicted that 2025 will be a pivotal year for AI implementation across the industry. This comes as <a href="https://www.benzinga.com/news/global/24/11/42156160/palantir-price-target-raised-to-75-by-dan-ives-amid-288-ytd-surge-analyst-calls-2025-a-primetime-year-for-ai">Palantir continues its impressive ascent</a>, having surged 288% year-to-date.
In a sector-wide upgrade, Ives raised Palantir's price target to $75, signaling broader confidence in the software sector's AI potential. The last close price for PLTR was $64.65, marking a 0.47% increase.
The AMD Trade
The Wood-led firm purchased 10,753 shares of AMD worth $1.5 million on Monday. The last close price for AMD was $141.13, marking a 2.01% increase.
Ark Invest&#8217;s trade in AMD comes as the company reportedly plans to enter the mobile device market with new accelerated processing unit (APU) chips designed for smartphones. These chips will leverage <a href="https://www.benzinga.com/media/24/11/42168509/amd-teams-up-with-taiwan-semi-to-take-on-samsung-in-smartphone-market">Taiwan Semiconductor Manufacturing Co's 3nm process</a>, extending Taiwan Semiconductor's order visibility for 3nm production into late 2026.
See Also: <a href="https://www.benzinga.com/markets/24/11/42152947/satellite-images-reveal-north-korea-reportedly-receiving-illicit-oil-from-russia?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Satellite Images Reveal North Korea Reportedly Receiving Illicit Oil from Russia</a>
AMD is also boosting its presence in India, with a $400 million investment aimed at enhancing its R&amp;D capabilities and tapping into the burgeoning market.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/42153356/is-warren-buffett-preparing-for-a-market-downturn-with-berkshire-hathaways-325b-cash-pile-analyst-says-internet-bubble-and-2008-crash-may-have-lessons?itm_source=parsely-api" target="_blank" rel="noopener">Is Warren Buffett Preparing For A Market Downturn With Berkshire Hathaway&#8217;s $325B Cash Pile? Analyst Says</a>
Other Key Trades:
<ul>
<li>Ark Invest&#8217;s ARKF fund sold shares of SoFi Technologies Inc and bought shares of Ibotta Inc.</li>
<li>The ARKG fund sold shares of Butterfly Network Inc and bought shares of Recursion Pharmaceuticals Inc.</li>
<li>The ARKW fund bought shares of 3iQ Ether Staking ETF and sold shares of Genius Sports Ltd.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42152684/musk-tweet-sparks-dogecoin-surge-fuels-speculation-on-x-payments?itm_source=parsely-api" target="_blank" rel="noopener">Musk Tweet Sparks Dogecoin Surge, Fuels Speculation On X Payments</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

AMZN

ARKK

ARKQ

PLTR

Cathie Wood-Led Ark Invest's Latest Portfolio Maneuver: Dumps Tesla And Palantir Shares, Buys Amazon And AMD Stock

Wedbush analyst Dan Ives has reaffirmed his $75 price target on Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), citing strong growth potential amid the AI revolution.
What Happened: On Monday, while appearing in a segment of CNBC, Ives argued that the market is undervaluing Palantir&#8217;s potential, especially in the software sector.
He highlighted that the company&#8217;s enterprise solutions could generate billions in revenue, positioning Palantir as a future leader like Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>).&nbsp;
Despite the current market price hovering around $37, Ives remains optimistic about Palantir&#8217;s growth trajectory in the coming years.
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42169194/joby-gets-toyotas-500m-dollar-lift-evtol-pioneer-making-new-highs?itm_source=parsely-api">Joby Gets Toyota&#8217;s $500M Dollar Lift: eVTOL Pioneer Making New Highs</a>
He acknowledged the skepticism from bears but maintained that the company&#8217;s advancements in AI and software use cases are unparalleled.
"The haters will continue to hate," Ives said, adding, "They are still underestimating when it comes to the software, the use cases." He continued by saying that there's no product out there that matches what Palantir has done with AIP.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Dan Ives breaks down why <a href="https://twitter.com/search?q=%24PLTR&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PLTR</a> is just scratching the surface &#x1f44f; <a href="https://t.co/W3hSrOhBAG">pic.twitter.com/W3hSrOhBAG</a>
&mdash; Tom Nash (@iamtomnash) <a href="https://twitter.com/iamtomnash/status/1861125940585082987?ref_src=twsrc%5Etfw">November 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Palantir&#8217;s Advanced Intelligence Platform or AIP, introduced in April 2023, integrates advanced AI features like large language models into the company's Foundry and Gotham platforms. It aims to streamline decision-making in sectors such as defense and intelligence.
Why It Matters: The endorsement from Ives comes as Palantir experiences a remarkable ascent, with its stock <a href="https://www.benzinga.com/news/global/24/11/42156160/palantir-price-target-raised-to-75-by-dan-ives-amid-288-ytd-surge-analyst-calls-2025-a-primetime-year-for-ai">surging 289.928% year-to-date</a>.
Ives has previously raised Palantir's price target to $75, highlighting 2025 as a pivotal year for AI implementation across the industry.
This optimism is shared with other software companies like Elastic NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) and Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), which were also upgraded to Buy ratings.
Despite the bullish outlook, some analysts have <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42039361/palantir-soars-to-150b-market-cap-as-analysts-flag-risks-in-valuation-insider-sales">flagged risks in Palantir&#8217;s valuation</a>. Hedge fund titans like Renaissance Technologies and ARK Investment Management have trimmed their stakes, selling over 3 million shares in the third quarter, although they still hold significant positions.
Palantir&#8217;s third-quarter earnings report <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">showed a revenue beat</a>, with total revenue up 30% year-over-year, driven by &#8220;unrelenting AI demand.&#8221;
U.S. revenue grew 44% year-over-year, with commercial and government sectors showing significant growth, further supporting Ives&#8217; bullish stance.
Price Action: Palantir's stock finished Monday at $64.65, up 0.47% during regular trading. However, it dropped 1.24% in after-hours trading, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
Photo by Spyro the Dragon on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/24/11/42151510/jensen-huangs-nvidia-fast-tracks-samsungs-ai-memory-certification-as-ai-giant-looks-to-catch-up-to-demand?itm_source=parsely-api">Jensen Huang&#8217;s Nvidia Fast-Tracks Samsung&#8217;s AI Memory Certification As AI Giant Looks To Catch Up To Demand</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

ESTC

ORCL

SNOW

Dan Ives Defends $75 Palantir Target Amid AI Revolution And Revenue Surge: 'Haters Will Continue To Hate'

JAGX and GNPX among Health Care movers

XTIA, PSNL and LIDR among mid-day movers

Andean Precious Metals Corp (APM) has gained Wednesday morning, with the stock increasing 888.10% in pre-market trading to 8.3. APM's short-term technical score of 55 indicates that the stock has traded more bullishly over the last month than 55% of stocks on the market. In the Biotechnology industry, which ranks 100 out o

Andean Precious Metals Corp (APM) has risen 888.10% Wednesday In Premarket Trading

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The best <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> to buy are in companies that put a lot of resources into research and development, often with nothing to show for it for years. 



Regulatory hurdles make finding biotech stocks to buy challenging if you don&rsquo;t have the patience to wait it out.



But when biotech companies win approval to sell and marketing a drug, the potential for profits can be off the charts. That&rsquo;s why it&rsquo;s a good idea to at least consider biotech, and whether they have a spot in your portfolio.



Biotech stocks represent companies involved in the research, development and commercialization of biological-based products that are designed to improve health. These companies can include pharmaceuticals, biotechnology, medical devices, and healthcare services.



While the industry is challenging because of the regulatory approval process and keen competition, biotech stocks do have some significant advantages. 



For example, they are relatively immune to economic downturns. Even when the economy does poorly, people and insurance companies will spend money on monthly medications they need to improve their quality of life. 



As the population ages, healthcare spending for pharmaceuticals and other medical products will continue to increase.



We&rsquo;re using the Portfolio Grader to find the best biotech stocks to buy in today&rsquo;s market. Each of these stocks gets top grades.



<h2>Eli Lilly &amp; Co. (LLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/lly_eli_lilly_1600-300x169.png" alt="Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI"><div>Source: Jonathan Weiss / Shutterstock.com</div></div>Weight loss drugs are one of the most popular trends in the biotech industry right now, with an estimated <a href="https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity">42% of the U.S. population</a> considered obese. That&rsquo;s why the first two companies on our list are top picks, both of them are soaring on the strength of their weight loss medications.



The U.S.-based company in this equation is Eli Lilly &amp; Co. (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/">LLY</a>), which markets its obesity drug under the name Zepbound. About 1 in 3 people who took the injectable drug at its highest dose (15 mg) report losing more than 58 pounds over a 72-week period.



The drug in Zepbound, tirzepatide, is also used in another highly successful Lilly product called Mounjaro, which is used to treat type 2 diabetes. Analysts believe that Zepbound can eventually be worth $25 billion a year in sales, and that Mounjaro sales could jump from $5.2 billion in 2023 to $16 billion in 2024.



<h2>Novo Nordisk (NVO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/nvo-stock-300x169.jpg" alt="Novo Nordisk logo on a corporate building"><div>Source: joreks / Shutterstock.com</div></div>The European entry into this equation is Novo Nordisk (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>), which has an injectable weight loss drug of its own called Wegovy. Wegovy was approved in 2021 in the U.S. to treat obesity and recently expanded to the U.K.



Expansion came with some growing pains, though. Some pharmacies continue to report shortages, and Novo Nordisk <a href="https://www.novonordisk-us.com/supply-update.html">says</a> its running its manufacturing lines 24 hours a day to try to maintain the supply.



Norvo Nordisk also manufactures the drug Ozempic as a treatment for type 2 diabetes, but doctors have also prescribed it as a treatment for weight loss.



NVO saw <a href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167013">revenue</a> of $21.4 billion in the fourth quarter, up 31% from the previous year. Profits of $7.7 billion were a 51% increase from the previous year.



NVO stock is up 20% in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Corbus Pharmaceuticals (CRBP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/crbp1600-300x169.png" alt="Corbus Pharmaceuticals (CRBP) leads in developing innovative drugs to treat inflammatory and fibrotic diseases. Exceptional quality patient focus"><div>Source: MacroEcon / Shutterstock.com</div></div>Corbus Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/crbp-stock-quote/">CRBP</a>) is a Massachusetts-based drugmaker specializing in oncology treatments. The company has potential drugs in its pipeline to treat solid tumors with antibody drug conjugates and monoclonal antibodies.



The most advanced treatment is treating U.S. patients with metastatic urothelial cancer <a href="https://www.corbuspharma.com/press-releases/detail/410/corbus-announces-dosing-of-first-patient-in-u-s-phase-1">in a trial study</a>.



Corbus also started work on a treatment for obesity and related conditions, although trials for that aren&rsquo;t expected to begin until the fourth quarter of this year.



Corbus doesn&rsquo;t have revenue coming in yet, so it&rsquo;s seeing steep losses &ndash; $8 million in the fourth quarter and $44.6 million for the full year. But that&rsquo;s expected for a biotech stock that has drugs in the pipeline but none yet for sale. You have to be willing to ride it out.



Many investors are. CRBP stock is up more than 500% so far this year as the market reacts to positive developments in the company&rsquo;s clinical trials. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Aptorum Group (APM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/apm-stock-1-300x169.jpg" alt="A magnifying glass zooms in on the website for Aptorum Group (APM)."><div>Source: Pavel Kapysh / Shutterstock.com</div></div>Aptorum Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/apm-stock-quote/">APM</a>) is a U.K.-based pharmaceutical company developing oncology and infectious diseases treatments. 



Its approach includes screening approved drug molecules and using its research platform to seek and develop new treatments and therapies.



The company recently agreed to a <a href="https://www.marketwatch.com/story/aptorum-group-to-merge-with-yoov-group-split-off-legacy-assets-28822b75">reverse merger</a> between its wholly owned subsidiary and YOOV Group, specializing in AI techniques to optimize business operations. &nbsp;APM shareholders will own 10% of the combined company after the merger.



Aptorum also plans to split off its legacy business assets into a subsidiary to be called Aptorum Therapeutics.



News of the merger and restructuring turbocharged APM shares, which are now up 264% in 2024. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Merck &amp; Co. (MRK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/mrk-stock-3-300x169.jpg" alt="Merck (MRK) logo outside of corporate building"><div>Source: Atmosphere1 / Shutterstock.com</div></div>Merck &amp; Co. (NYSE:<a href="https://investorplace.com/stock-quotes/mrk-stock-quote/">MRK</a>) is a New Jersey-based pharmaceutical company best known for its Keytruda cancer treatment. Keytruda brought in <a href="https://www.fiercepharma.com/pharma/whos-no-1-25b-sales-mercks-keytruda-appears-set-be-top-selling-drug-2023">$25 billion</a> in sales in 2023, making it the top-selling drug in the world.



But Merck also has many other drugs on the market, including Gardasil for human papillomavirus; ProQuad, which is a vaccine for measles, mumps, rubella and chickenpox; and Januvia for type 2 diabetes. And that&rsquo;s important, as Merck will lose exclusivity for Keytruda in 2028, making it available for generic substitutes.



Merck expanded that pipeline last month by <a href="https://www.merck.com/news/merck-completes-acquisition-of-harpoon-therapeutics-inc/">completing its acquisition</a> of Harpoon Therapeutics. The company&rsquo;s lead drug candidate treats small cell lung cancer and neuroendocrine tumors.



Earnings for the <a href="https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2023-financial-results/">fourth quarter</a> included revenue of $14.6 billion, up 6% from a year ago. The company reported a loss of $1.2 billion and 48 cents per share as part of previously announced charges incurred in its deal with Daiichi Sankyo to jointly develop three cancer treatments.



MRK stock is up 16% in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Gyre Therapeutics (GYRE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Gyre Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/gyre-stock-quote/">GYRE</a>) is a North Carolina-based biotech company developing treatments for organ fibrosis and inflammatory diseases. 



The company completed a Phase 2 trial in China for its treatment of hepatitis B-induced liver fibrosis.



It&rsquo;s now planning a Phase 2 trial for the treatment in the U.S. The drug candidate, Hydronidone, is a structural analog of pirfenidone, which is already approved in the U.S. and China for the treatment of idiopathic pulmonary fibrosis.



The company says there are more than 140 million people who have liver fibrosis from hepatitis B, with no approved therapies on the market. So, its treatment has the potential to be profitable for investors.



Gyre posted full-year revenue in 2023 of $113.5 million, up from $102.3 million in 2022.



GYRE stock is up 330% in the last 12 months, but has been falling so far in 2024. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Neurogene (NGNE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/bio1600-300x169.jpg" alt="MRNA Stock Will Continue Its Slump, but a $25 It Will Be a Great Buy"><div>Source: Shutterstock</div></div>Neurogene (NASDAQ:<a href="https://investorplace.com/stock-quotes/ngne-stock-quote/">NGNE</a>) is a biotech company that is developing what it calls EXACT gene therapy technology. 



The platform can be used to achieve optimized levels of transgene expression for each drug candidate, which Neurogene says gives it an advantage over traditional gene therapy.



It&rsquo;s currently working with the platform to develop its lead gene therapy candidate for Rett syndrome, which is a disorder seen in children that impairs their ability to walk, eat, speak or breathe.



The company went public just last year in a <a href="https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-closing-merger-neoleukin-therapeutics-and">reverse merger</a> with cancer drug developer Neoleukin Therapeutics backed by investment firms that put $95 million into the newly formed company. The investment is expected to <a href="https://ir.neurogene.com/news-releases/news-release-details/neurogene-reports-fourth-quarter-and-full-year-2023-financial">assure Neurogene of funding</a> until the second half of 2026.



That gives it a solid window to develop and get approvals.



NGNE stock is up 95% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



On the date of publication, Louis Navellier held LLY and NVO. He did not have (either directly or indirectly) any other positions in the securities mentioned in this article.



The InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/04/7-a-rated-aggressive-biotech-stocks-to-bet-on-in-2024/">7 A-Rated Aggressive Biotech Stocks to Bet On in 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

CGC, GENE and HOLO among mid-day movers

Aptorum Group (APM) has released an update. Aptorum Group, a biopharmaceutical company, has reported a decreased net loss of $4.3 million for the f...

Aptorum Group Reports Decreased Annual Loss

Aptorum Group reports FY results

Aptorum Group (APM) has released an update. Aptorum Group Limited has announced an amendment to extend the term of its Merger Agreement with YOOV G...

Aptorum Group Extends Merger Agreement Term

Aptorum Group (APM) has released an update. Aptorum Group Limited announced the resignation of two directors, Dr. Mirko Scherer and Mr. Charles Bat...

Aptorum Group Board Sees Key Resignations

Aptorum Group (APM) has released an update. Aptorum Group has scheduled its 2024 Annual General Meeting for December 10 in Hong Kong, where shareho...

Comments

Aptorum Gr

Aptorum Gr (APM) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga